Optimind Pharma

Optimind Pharma ROE

The Return on Equity (ROE) of Optimind Pharma (OMND.CN) as of Oct 18, 2026 is 288.50 %. In the previous year, Return on Equity (ROE) was 1,083.41 % — a change of -73.37% (lower).

ROE

288.50 %

YoY

-73.37%

Last updated:

In 2025, Optimind Pharma's return on equity (ROE) was 288.50 %, a -73.37% increase from the 1,083.41 % ROE in the previous year.

The Optimind Pharma ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2017
-30.53 CAD
Jan 1, 2018
20.90 CAD
Jan 1, 2019
2.35 CAD
Jan 1, 2020
-162.79 CAD
Jan 1, 2021
104.23 CAD
Jan 1, 2023
-481.13 CAD
Jan 1, 2024
1,083.41 CAD
Jan 1, 2025
288.50 CAD
The Optimind Pharma ROE history
YEARROEYoY
288.50 %-73.37%
1,083.41 %-325.18%
-481.13 %-561.60%
104.23 %-164.03%
-162.79 %-7,033.09%
2.35 %-88.77%
20.90 %-168.48%
-30.53 %-337.04%
12.88 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Optimind Pharma Stock analysis

What does Optimind Pharma do? Optimind Pharma Corp, headquartered in London, Ontario, provides medical cannabis and ketamine-assisted treatment for mental health conditions such as PTSD, anxiety, and depression. The company offers two treatment types—monotherapy and assisted therapy—using ketamine capsules, with effects felt within 30 minutes and cognitive restoration within two hours. It partners with psilocybin treatment developers to expand its therapeutic programs, which integrate psychedelic medicine with therapeutic processing based on scientific research. Optimind Pharma is one of the most popular companies on Eulerpool.

ROE Details

Decoding Optimind Pharma's Return on Equity (ROE)

Optimind Pharma's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Optimind Pharma's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Optimind Pharma's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Optimind Pharma’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Optimind Pharma stock

Return on Equity (ROE) of Optimind Pharma is 288.50 % in 2025.

Return on Equity (ROE) of Optimind Pharma changed from 1,083.41 % to 288.50 %, representing a -73.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Optimind Pharma since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Optimind Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Optimind Pharma

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Optimind Pharma